-$0.24 EPS Expected for Sio Gene Therapies Inc. (NASDAQ:SIOX) This Quarter

Equities analysts expect Sio Gene Therapies Inc. (NASDAQ:SIOXGet Rating) to announce ($0.24) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sio Gene Therapies’ earnings. Sio Gene Therapies posted earnings per share of ($0.19) in the same quarter last year, which would suggest a negative year over year growth rate of 26.3%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Sio Gene Therapies will report full-year earnings of ($1.04) per share for the current financial year. For the next year, analysts anticipate that the company will report earnings of ($1.18) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Sio Gene Therapies.

Sio Gene Therapies (NASDAQ:SIOXGet Rating) last posted its quarterly earnings data on Friday, February 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09).

A number of equities analysts have recently weighed in on SIOX shares. Zacks Investment Research raised shares of Sio Gene Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. SVB Leerink lowered shares of Sio Gene Therapies from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $6.00 to $1.00 in a research report on Tuesday, February 1st. HC Wainwright lowered shares of Sio Gene Therapies from a “buy” rating to a “sell” rating in a research report on Thursday, April 28th. Finally, Cantor Fitzgerald lowered shares of Sio Gene Therapies from an “overweight” rating to a “neutral” rating and set a $0.80 price target for the company. in a research report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $4.43.

Shares of NASDAQ:SIOX remained flat at $$0.29 during trading on Friday. 416,836 shares of the stock were exchanged. The firm’s fifty day moving average is $0.59 and its two-hundred day moving average is $1.09. The firm has a market cap of $21.15 million and a PE ratio of -0.34. Sio Gene Therapies has a twelve month low of $0.27 and a twelve month high of $2.95.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SIOX. Two Sigma Securities LLC purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $28,000. Marshall Wace LLP purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $103,000. Morgan Stanley boosted its stake in shares of Sio Gene Therapies by 136.5% in the third quarter. Morgan Stanley now owns 68,383 shares of the company’s stock valued at $149,000 after purchasing an additional 39,471 shares during the period. Franklin Resources Inc. purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $179,000. Finally, State Street Corp raised its holdings in Sio Gene Therapies by 42.9% in the fourth quarter. State Street Corp now owns 157,200 shares of the company’s stock valued at $203,000 after acquiring an additional 47,200 shares in the last quarter.

Sio Gene Therapies Company Profile (Get Rating)

Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.

Further Reading

Get a free copy of the Zacks research report on Sio Gene Therapies (SIOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sio Gene Therapies (NASDAQ:SIOX)

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.